Substance / Medication

Probenecid

Overview

Active Ingredient

probenecid

RxNorm CUI

8698

Indications

Probenecid tablets are indicated for the treatment of the hyperuricemia associated with gout and gouty arthritis.As an adjuvant to therapy with penicillin or with ampicillin, methicillin, oxacillin, cloxacillin, or nafcillin, for elevation and prolongation of plasma levels by whatever route the antibiotic is given.

Labeler: Rising Pharma Holdings, Inc.Updated: 2026-01-28T00:00:00.000ZFull label on DailyMed

Contraindications

When this intervention should not be used

Hypersensitivity to probenecid.Children under 2 years of age.Not recommended in persons with known blood dyscrasias or uric acid kidney stones.Therapy with probenecid should not be started until an acute gouty attack has subsided.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Gonorrhea

Neurosyphilis

Gout

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

3 trials linked to this intervention

Total Trials

Recruiting

With Results

Recent Trials

TRPV2 Agonists in the Fontan Circulation

NCT03965351Phase 4Completed8 enrolled

Comparison of Two Drugs, Cidofovir and Ganciclovir, in Treating Patients With AIDS Who Have CMV Retinitis

NCT00000894Phase 4Completed300 enrolled

Evaluation of Alternative Oseltamivir (Tamiflu) Dosing Strategies.

NCT00304434Phase 4Completed48 enrolled

View all 3 trials on ClinicalTrials.gov

Research Evidence

Published studies and systematic reviews

Sort:

Addition of probenecid to oral β-lactam antibiotics: a systematic review and meta-analysis.

Wilson Richard C, Arkell Paul, Riezk Alaa et al. · J Antimicrob Chemother · 2022

PMID: 35726853Meta-AnalysisFull text (PMC)

Towards pharmacokinetic boosting of phenoxymethylpenicillin (penicillin-V) using probenecid for the treatment of bacterial infections.

Wilson Richard C, Riezk Alaa, Arkell Paul et al. · Sci Rep · 2024

PMID: 39034340RCTFull text (PMC)

Oral Probenecid for Nonhospitalized Adults with Symptomatic Mild-to-Moderate COVID-19.

Martin David E, Pandey Neelam, Chavda Purvi et al. · Viruses · 2023

PMID: 37515194RCTFull text (PMC)

Combination of Amoxicillin 3000 mg and Probenecid Versus 1500 mg Amoxicillin Monotherapy for Treating Syphilis in Patients With Human Immunodeficiency Virus: An Open-Label, Randomized, Controlled, Non-Inferiority Trial.

Ando Naokatsu, Mizushima Daisuke, Omata Kazumi et al. · Clin Infect Dis · 2023

PMID: 37157863RCT

Validation of a Drug Transporter Probe Cocktail Using the Prototypical Inhibitors Rifampin, Probenecid, Verapamil, and Cimetidine.

Wiebe Sabrina T, Giessmann Thomas, Hohl Kathrin et al. · Clin Pharmacokinet · 2020

PMID: 32504272RCTFull text (PMC)

Probenecid Improves Cardiac Function in Subjects with a Fontan Circulation and Augments Cardiomyocyte Calcium Homeostasis.

Rubinstein Jack, Woo Jessica G, Garcia Anastacia M et al. · Pediatr Cardiol · 2020

PMID: 32770262RCTFull text (PMC)

Inhibitory Effects of Probenecid on Pharmacokinetics of Tenofovir Disoproxil Fumarate and Emtricitabine for On-Demand HIV Preexposure Prophylaxis.

Liu Stephanie N, Gufford Brandon T, Lu Jessica Bo Li et al. · Clin Pharmacol Ther · 2020

PMID: 31675437RCTFull text (PMC)

Probenecid Improves Cardiac Function in Patients With Heart Failure With Reduced Ejection Fraction In Vivo and Cardiomyocyte Calcium Sensitivity In Vitro.

Robbins Nathan, Gilbert Mark, Kumar Mohit et al. · J Am Heart Assoc · 2018

PMID: 29331959RCTFull text (PMC)

Investigation of Drug-Drug Interactions Between Ritobegron, a Selective β3 -Adrenoceptor Agonist, With Probenecid in Healthy Men.

Abe Yoshikazu, Nakano Yuki, Kanazawa Toru et al. · Clin Pharmacol Drug Dev · 2016

PMID: 27163499RCT

Inhibitory effects of p-aminohippurate and probenecid on the renal clearance of adefovir and benzylpenicillin as probe drugs for organic anion transporter (OAT) 1 and OAT3 in humans.

Maeda Kazuya, Tian Ying, Fujita Tomoe et al. · Eur J Pharm Sci · 2014

PMID: 24747579RCT

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type: Substance / Medication
Fully Specified Name: Probenecid (substance)
SNOMED CT: 387365004
UMLS CUI: C0033209
RxNorm CUI: 8698
Labeler: Rising Pharma Holdings, Inc.

Clinical Data

This intervention maps to 3 entities in the Healos knowledge graph.

Conditions

Biomarkers

Specialists

Symptoms

Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.